KRAS G12C Inhibitors in mCRC
A brief discussion regarding current data and interest in treating appropriate patients with metastatic colorectal cancer with potent KRAS G12C selective inhibitors.
Future Directions in mCRC
Drs Jaffer A. Ajani and Zev A. Wainberg comment on current obstacles surrounding the treatment of metastatic colorectal cancer and consider the future use of ctDNA as more is learned about the disease.
EGFR Therapy for mCRC: Dermatologic Toxicity
Best practices for managing skin rashes associated with anti-EGFR therapy for metastatic colorectal cancer.
Later-Line Treatment Options for mCRC
Recommendations for treating patients with relapsed/refractory metastatic colorectal cancer in the third-line or later settings with regorafenib or TAS-102 therapy.
Sequencing Anti-EGFR Therapy in mCRC
The importance of aligning second-line treatment decisions with patient goals in metastatic colorectal cancer, and the benefits of treating patients with biweekly cetuximab, especially during the COVID-19 pandemic.
Changes in Cetuximab Dosing Schedule in mCRC
Reactions to recent changes approved by the FDA to the dosing schedule of cetuximab for metastatic colorectal cancer and the value of real-word data on clinical practice patterns in the community when administering this drug.
Selecting Systemic Therapy for Newly Diagnosed mCRC
Treatment approaches available for patients with newly diagnosed metastatic colorectal cancer that is RAS wild type and factors that impact decisions for utilizing a 2-drug versus 3-drug regimen.
Next-Generation Sequencing in Metastatic Colorectal Cancer
Drs Jaffer A. Ajani and Zev A. Wainberg comment on the rationale for conducting full next-generation sequencing panels on patients with metastatic colorectal cancer and explain how to best utilize information provided to inform treatment decisions.
Molecular Testing in Metastatic Colorectal Cancer
The significance of studying genomics in metastatic colorectal cancer and an overview of actionable targets that can be tested for to help in treatment decisions for newly diagnosed disease.
Trends in Colorectal Cancer Incidence
Dr Jaffer A. Ajani highlights the increasing incidence of colorectal cancer diagnoses in younger patients as a growing concern during a discussion on trends in prevalence.
Pancreatic Cancer Updates
Liver Cancer Updates
Gastric Cancer Updates
Colorectal Cancer Updates
Dr. Ajani on Clinical Implications of Trastuzumab Deruxtecan in Gastric and GEJ Adenocarcinoma
Jaffer A. Ajani, MD, discusses the potential clinical implications of fam-trastuzumab deruxtecan-nxki in gastric or gastroesophageal junction adenocarcinoma if approved by the FDA.
Obe-Cel Elicits High Remission Rates in R/R B-ALL Irrespective of Leukemic Burden
Adding Navitoclax to Ruxolitinib Doubles Spleen Volume Reductions for Myelofibrosis
MRD Positivity Correlates With Allogeneic Transplant Benefits in NPM1-Mutated AML
Orca-T Shows High Survival Rates in Intermediate-/High-Risk Myelodysplastic Syndrome
2 Clarke Drive Cranbury, NJ 08512